PUNE, India, March 01, 2023 (GLOBE NEWSWIRE) — The global In vitro diagnostics market The size reached USD 92.08 billion in 2021. The market value is projected to increase from US$71.43 billion in 2022 to US$107.42 billion in 2029, showing a CAGR of 6.0% over the forecast period. In vitro diagnostics (IVD) includes medical devices that use biological samples such as blood, urine, and tissue to perform diagnostic tests. The IVD tests help detect and monitor infectious diseases, autoimmune diseases, and a variety of medical conditions, as well as analyze drug therapies, according to Fortune Business Insights^TM in his report titled “In Vitro Diagnostic Devices Market, 2022–2029”.

key industry development

• Thermo Fisher Scientific acquired Mesa Biotech, Inc., a maker of point-of-care molecular diagnostic devices.
• BD announced that the U.S. FDA has granted emergency use authorization (EUA) for a new rapid antigen test to detect SARS-CoV-2, influenza A and influenza B in a single test.
• BD and Scanwell Health have announced a collaboration to develop a rapid, at-home test for SARS-CoV-2 using a BD antigen test and Scanwell Health’s mobile app.

Request a free sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/in-vitro-diagnostics-ivd-market-101443

Report scope:

The central theses

• Launch of the Cobas pulse point-of-care blood glucose meter by F. Hoffmann-La Roche Ltd. This new product, the predecessor of Accu-Chek Inform II, is expected to be.
• According to the EUA, Abbott has also rolled out a molecular test in the United States to identify COVID-19 on its ID NOW rapid point-of-care technology.
• According to the World Health Organization (WHO), 17.9 million people die from cardiovascular diseases (CVDs), which are the leading cause of…